儿童肺炎支原体肺炎临床路径实施效果评价

临床儿科杂志 ›› 2014, Vol. 32 ›› Issue (6): 528-531.

儿童肺炎支原体肺炎临床路径实施效果评价

朱丽丽，张海邻，温顺航，张艳，李昌崇

温州医科大学附属育英儿童医院（浙江温州　325027）

收稿日期:2013-11-29 出版日期:2014-06-15 发布日期:2014-06-15

Evaluations of the clinical pathway in children with Mycoplasma pneumoniae pneumonia　

ZHU Lili, ZHANG Hailin, WEN Shunhang, ZHANG Yan, LI Changchong

(Department of Respiratory, The Affiliated Yuying Children's Hospital, Wenzhou Medical University, Wenzhou 325027, Zhejiang, China)

Received:2013-11-29 Online:2014-06-15 Published:2014-06-15

摘要/Abstract

摘要：

　目的　评估肺炎支原体肺炎（MPP）临床路径的实施效果。方法　采用回顾性研究方法，分析并比较采用临床路径治疗的145例和非临床路径治疗的45例MPP患儿在住院时间、住院费用、治愈率等方面的差异，并探讨临床路径的变异情况。结果　临床路径组的住院时间为9 d(6~10 d)，短于非临床路径组的10 d(7~12.5 d)，差异有统计学意义（P=0.003）；治愈率93.8%，高于非临床路径组的84.4%，差异有统计学意义（P=0.043）；住院费用为4 696.5元(3 608.3~5 677.6元)，高于非临床路径组的3 175.3元(2 490.8~4 585.0元)，差异有统计学意义（P<0.001）。临床路径变异率48.3%（70/145）。结论　实施MPP临床路径可提高治愈率，缩短住院时间，但该路径在临床实施过程中变异率较高，仍需加以完善并推广使用。

Abstract: 　Objective　To investigate the efficacy of the clinical pathway introduced in children with Mycoplasma pneumoniae pneumonia (MMP). Methods Based on a retrospective study, the length of hospital stay, hospital expenses and curative rate were compared between 145 MMP patients managed according to clinical pathway and other 45 MMP patients. The causes of variation were analyzed in the clinical pathway group as well. Results The length of hospital stay in clinical pathway group [9 (6~10) days] was significantly shorter than that in the control group [10 (7-12.5) days] (P=0.003). The curative rate (93.8%) was significantly higher than that in the control group (84.4%) (P=0.043). The hospital expenses [4 696.5 (3 608.3-5 677.6) CNY] was significantly higher than that in the control group [3175.3 (2490.8-4585.0) CNY] (P<0.001). The variation rate of clinical pathway was 48.3% (70/145 cases) in clinical pathway group. Conclusions The curative rate is improved and the length of hospital stay is shortened after the clinical pathway is introduced in MMP children. However, there is a high variation rate in the clinical pathway. It is necessary to optimize the clinical pathway before it is adapted in clinic.

朱丽丽，张海邻，温顺航，张艳，李昌崇. 儿童肺炎支原体肺炎临床路径实施效果评价[J]. 临床儿科杂志, 2014, 32(6): 528-531.

ZHU Lili,ZHANG Hailin,WEN Shunhang,ZHANG Yan,LI Changchong. Evaluations of the clinical pathway in children with Mycoplasma pneumoniae pneumonia　[J]. , 2014, 32(6): 528-531.

参考文献

[1] Youn YS，Lee KY，Hwang JY，et al. Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia [J]. BMC Pediatr，2010，10：48.
[2] Shah SS，Test M，Sheffler-Collins S，et al. Macrolide therapy and outcomes in a multicenter cohort of children hospitalized with Mycoplasma pneumoniae pneumonia [J]. J Hosp Med，2012，7(4)：311-317.
[3] 张冰，陈志敏. 2000—2006年杭州市三岁以上儿童肺炎支原体肺炎临床特征变化趋势 [J]. 中华儿科杂志，2010，48(7)：531-534.
[4] 胡亚美，江载芳. 诸福棠实用儿科学 [M]. 7版. 北京：人民卫生出版社，2002：1204-1205.
[5] 吴袁剑云，英立平. 临床路径实施手册 [M]. 北京：北京医科大学出版社，2006：99.
[6] 王秀娟，王瑞芹，万东华，等. 临床路径在儿童支气管肺炎治疗中的卫生经济学评价 [J]. 齐齐哈尔医学院报，2009，30(3)：318-319.
[7] 王利珍，于宗君. 临床路径在肺炎支原体肺炎患儿治疗中的应用 [J]. 山东医药，2011，51(25)：5.
[8] Walker C，Danby S，Turner S. Impact of a bronchiolitis clinical care pathway on treatment and hospital stay [J]. Eur J Pediatr，2012，171(5)：827-832.
[9] 孙玉红，杨永清. 临床路径的变异研究进展 [J]. 全科护理，2010 ，8(4)：909-911.
[10] 陈玲玲，成云改，陈志敏，等. 肺炎支原体肺炎患儿混合感染的研究 [J]. 中华儿科杂志，2012，50(3)：211-215.
[11] Zhao F，Liu G，Wu J，et al. Surveillance of macrolide resistant Mycoplasma pneumoniae in Beijing，China from 2008 to 2012 [J]. Antimicrob Agents Chemother，2013，57(3)：1521-1523.
[12] Kawai Y，Miyashita N，Yamaguchi T，et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients [J]. Respirology，2012，17(2)：354-362.
[13] Okada T，Morozumi M，Tajima T，et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children [J]. Clin Infect Dis，2012，55(12)：1642-1649.
[14] Youn YS，Lee KY. Mycoplasma pneumoniae pneumonia in children [J]. Korean J Pediatr，2012，55(2)：42-47.
[15] 阎赢，韩杰，靳峰，等. 对临床路径管理试点工作中存在问题的建议和思考 [J].中国医院，2011，15(2)：11-12.